Related Experiment Video
Updated: Mar 25, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy
Teemu Taipale1, Kaisu Pienihäkkinen, Erika Isolauri
1Korpilahti-Muurame Health Care Center, 40950 Muurame, Finland. teemu.taipale@muurame.fi
Insights
Controlled administration of Bifidobacterium animalis subsp. lactis BB-12 (BB-12) probiotic in healthy infants may reduce respiratory infections. This study found fewer respiratory infections in infants receiving BB-12 compared to the placebo group.
Area of Science:
- Microbiology
- Pediatrics
- Immunology
Background:
- Probiotics, such as Bifidobacterium animalis subsp. lactis BB-12 (BB-12), are increasingly studied for their potential health benefits in infants.
- The impact of specific probiotic strains on the incidence of acute infectious diseases in early childhood requires further investigation.
Purpose of the Study:
- To evaluate the effect of controlled Bifidobacterium animalis subsp. lactis BB-12 (BB-12) administration on the risk of acute infectious diseases in healthy newborn infants.
- To assess the recovery of BB-12 in infant feces and its correlation with health outcomes.
Main Methods:
- A double-blind, placebo-controlled study involving 109 infants aged 1-8 months.
- Infants received either a BB-12 containing tablet or a placebo tablet twice daily via a pacifier or spoon.
- Data collected included breastfeeding habits, infections, symptoms, and fecal samples for BB-12 quantification using qPCR.
Main Results:
- BB-12 was detected in the feces of 62% of infants in the probiotic group.
- No significant differences were observed in gastrointestinal symptoms, otitis media, or antibiotic use between groups.
- Infants receiving BB-12 experienced significantly fewer respiratory infections (65%) compared to the control group (94%).
Conclusions:
- Controlled early childhood administration of Bifidobacterium animalis subsp. lactis BB-12 may reduce the incidence of respiratory infections.
- BB-12 supplementation appears to be a promising strategy for enhancing infant immune defenses against respiratory pathogens.
Abstract:
The impact of controlled administration of Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on the risk of acute infectious diseases was studied in healthy newborn infants. In this double-blind, placebo-controlled study, 109 newborn 1-month-old infants were assigned randomly to a probiotic group receiving a BB-12-containing tablet (n 55) or to a control group receiving a control tablet (n 54). Test tablets were administered to the infants twice a day (daily dose of BB-12 10 billion colony-forming units) from the age of 1-2 months to 8 months with a novel slow-release pacifier or a spoon. Breastfeeding habits, pacifier use, dietary habits, medications and all signs and symptoms of acute infections were registered. At the age of 8 months, faecal samples were collected for BB-12 determination (quantitative PCR method). The baseline characteristics of the two groups were similar, as was the duration of exclusive breastfeeding. BB-12 was recovered (detection limit log 5) in the faeces of 62% of the infants receiving the BB-12 tablet. The daily duration of pacifier sucking was not associated with the occurrence of acute otitis media. No significant differences between the groups were observed in reported gastrointestinal symptoms, otitis media or use of antibiotics. However, the infants receiving BB-12 were reported to have experienced fewer respiratory infections (65 v. 94%; risk ratio 0·69; 95% CI 0·53, 0·89; P = 0·014) than the control infants. Controlled administration of BB-12 in early childhood may reduce respiratory infections.
Related Concept Videos
Probiotics
Microbiota of the Stomach and Small Intestine
Development of the Oral Microbiota
Clinical Significance of Antibiotic Resistance
Development of Human Microbiota
Bacterial Phylum Firmicutes

